RxDoctor Payments Data

Sally Kim, MD

Internal Medicine · la Jolla, CANPI 1689635088

Payments from drug & device makers

$1,392in general payments, 2019–2025

Across 23 payments — averaging $60.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$223
  • Eyevance Pharmaceuticals LLC$173
  • Alcon$149
  • UCB, Inc.$129
  • AbbVie$125
  • Bausch & Lomb Americas Inc.$125
  • plus $467 from 8 others

What the payments were for

  • Food & beverage$1,38099%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,392 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$136,420
Medicare patients
320
Services billed
2,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide52$48,186
EliquisApixaban29$47,276
JardianceEmpagliflozin21$24,323
SynjardyEmpagliflozin/Metformin Hcl17$22,512
JanuviaSitagliptin Phosphate15$19,744
MyrbetriqMirabegron26$16,880
JanumetSitagliptin Phos/Metformin Hcl13$9,563
SynthroidLevothyroxine Sodium45$4,548
Rosuvastatin Calcium258$4,135
Atorvastatin Calcium375$3,803
Bupropion XlBupropion Hcl93$3,387
Valsartan68$2,723
Levothyroxine Sodium197$2,596
Losartan Potassium236$2,439
Pantoprazole Sodium123$1,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$58$48,18652 claims
Astellas Pharma US IncMyrbetriq$68$16,88026 claims
AbbVieSynthroid$125$4,54845 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →